Nanosphere Inc

Nanosphere — Investor Day (March 2014)

63 slides from Nanosphere's investor day presentation, Mar 20, 2014

  1. Slide 1: Nanosphere Investor Day March 20, 2014

    Nanosphere Investor Day March 20, 2014

  2. Slide 2: Forward-looking statements

    This presentation contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this presentation regarding our strategy, future operations, future financial position, future net

  3. Slide 3: Agenda

    agenda Company and Market Overview Michael McGarrity, President & CEO Customer Perspective on Solving the Sepsis Problem Bert Lopansri, MD - Intermountain Healthcare, Infectious Diseases Customer Perspective on Solving the Enteric Problem Nathan Ledeboer, PhD - Medical College of Wisconsin, Clinical

  4. Slide 4: Company and market overview

    Company and market overview 4 Michael mcgarrity President & Chief Executive officer

  5. Slide 5: Our mission

    Our mission Enhance Medicine Through Targeted Diagnostics Improve Patient Care Save lives Decrease morbidity Reduce spread of antibiotic resistance Lower Costs to the Healthcare System Shorter length of stay Antibiotic savings Demonstrated economic outcomes Deliver Exceptional Customer Service Value

  6. Slide 6: Why we believe we'll win

    Why we believe we'll win Installed Base Over 200 U.S. microbiology customers and growing Leverage through expanding menu Reliable and Versatile Technology Clinical evidence validates exceptional performance Detection of organism and drug resistance, proteins Flexible reporting enables lab to respond

  7. Slide 7: Two main drivers of molecular diagnostics markets

    7 TWO MAIN DRIVERS OF MDX MARKETS Sample-To- Result High Count Multi- Plexing Conversion of traditional culture-based methods to molecular will be driven by the need for rapid and clinically actionable results that will either improve outcomes or improve economics ACCOUNTABLE CARE Need for more time

  8. Slide 8: Filtering the competitive landscape, NSPH emerges as market leader

    Filtering the Competitive Landscape, NSPH Emerges as the Market Leader Multi- Plexed Targets >200 >200 >200 100 50 25 <5 <5 <5 Filter Sample -to- Result Filter High Count Multi- Plexing Competitive Filter Performance Price/Panel Protein Sample- To- Result No No No Yes No Yes Through 2015 Nanosphere

  9. Slide 9: Progress and future driven by proprietary markets

    2011 2012 2013 2014 2015 Nanosphere's Progress and Future Driven By Proprietary Markets BSI (~$300M) Nanosphere's Cumulative US Microbiology Placements Nanosphere's Cumulative US Microbiology Placements Nanosphere's Cumulative US Microbiology Placements Nanosphere's Cumulative US Microbiology Placem

  10. Slide 10: Solving the Enteric Problem

    Solving the Enteric Problem Large Market Opportunity 3.7 million U.S. emergency department visits in 2010 for unknown gastro- intestinal symptoms of bacterial or viral pathogens 1.3 million resulted in hospitalizations Costly to the Healthcare System U.S. patients suffering from gastrointestinal inf

  11. Slide 11: Superbugs are making headlines

    Superbugs are making headlines 11 Nanosphere investor day | Company and market overview

  12. Slide 12: CDC Landmark Recommendations

    CDC Landmark Recommendations Burden and Threat Posed by Antibiotic-Resistant Infections Drug resistant infections are a threat to human and economic health Overuse of antibiotics is the single most important factor Urgent action is needed NOW by everyone who uses antibiotics Four Core Actions Must B

  13. Slide 13: Solving the Sepsis Problem

    Solving the Sepsis Problem Validation of Value and Opportunity >200 Customers = 5% Across the spectrum of hospital classification Converting the Status Quo It has not been easy It takes data It takes experience It takes references Leverage in our Leadership Position Customer Perspective 13 Nanospher

  14. Slide 14: Clinical Impact of Rapid Bacterial Identification in Sepsis

    Clinical Impact of Rapid Bacterial Identification in Sepsis Bert K. Lopansri, MD Associate Professor of Medicine Division of Infectious Diseases Intermountain Medical Center

  15. Slide 15: Outline

    Outline What is the clinical importance of a rapid multiplex diagnostic test? Why is there a delay in adoption of novel diagnostic methods? What is the long term future of rapid multiplex diagnostic platforms?

  16. Slide 16: Fleming in reference to Penicillin

    Fleming in reference to Penicillin The public will demand [the drug and]...then will begin an era... of abuses. The microbes are educated to resist penicillin and a host of penicillin-fast organisms is bred out which can be passed to other individuals...In such a case the thoughtless person playing

  17. Slide 17: Then de-escalate when microbiology data available

    THEN DE-ESCALATE WHEN MICROBIOLOGY DATA AVAILABLE

  18. Slide 18: Why does acceptance of new technology take so long?

    Why does acceptance and implementation of new technology take such a long time?

  19. Slide 19: Barriers to adopting molecular test

    Barriers to adopting molecular test Clinician Skepticism Preserving the bottom line Prove Clinical Value Lack of awareness Misleading data No incentives to change Disruption to status quo No stakeholders

  20. Slide 20: Why does acceptance of new technology take such a long time?

    Why does acceptance of new technology take such a long time? technology take such a long time? technology take such a long time? Key elements Innovation Communication channels Time Social system Adoption process Knowledge Persuasion Decision Implementation Confirmation

  21. Slide 21: Studies of Rapid Diagnostic Tests

    Studies of Rapid Diagnostic Tests a. Katherine K. Perez. Arch Pathol Lab Med. 2013; 137:1247-1254. Karri A. Bauer. CID. (2010). 51(9):1074-1080. GN Forrest. JAC. (2006). 58; 154-158 GN Forrest. AAC. (2008). 52(10): 3558-3563. C. Holtzman. JCM. (2011) 49(4):1581-2. Platform Antibiotic Outcomes Cost S

  22. Slide 22: Innovation: Verigene BC-GP/BC-GN

    INNOVATION: Verigene BC-GP/BC-GN Multiple targets RESISTANCE MARKERS Gram Positive: mecA gene Van A/B genes Gram Negatives Carbapenemases: KPC, NDM, OXA, IMP, VIM ESBL: CTX-M

  23. Slide 23: Clinical Evaluation

    Clinical Evaluation Evaluated use of Verigene BC-GP for management of Staphylococcus aureus septicemia Verification: March - May 2013 Clinical evaluation: June - Sept 2013 Matched, historical controls

  24. Slide 24: Sa Bg Pa 2s Eo ES 3s re £5 = esoseo Ress uo}e9141}U ep!

    3 Sa 23 Bg Pa 58 2s 23 Eo 538 ES 5 3s re £5 5 = esoseo Ress uo}e9141}U ep! 0} (SANoY) eUL

  25. Slide 25: Impact of rapid identification on MSSA septicemia

    Impact of rapid identification on MSSA septicemia Lopansri, unpublished Supported by Nanosphere, Inc BC-GP N=50 Control N=100 P Duration of empiric antibiotics (hours) 24.4 [15.7, 34.8] 52 [49,62] 0.001 Days of vancomycin therapy 1 [1, 2] 3 [2, 3] 0.001 Mean number vanco doses 1.5 (1, 2) 3.5 [3, 4]

  26. Slide 26: Impact of BC-GP on cost

    Impact of BC-GP on cost BC-GP Control P Total Cost $18,688 [$15,902, $25,751] N=65 $26,143 [$21,480, $31,758] N=130 0.11 MSSA $17,026 [$13,595, $22,169] N=50 $22,927 [$18,969, $29,318] N=100 0.03 Lopansri, unpublished Supported by Nanosphere, Inc

  27. Slide 27: Barriers to adopting molecular test

    Barriers to adopting molecular test Clinician Skepticism Preserving the bottom line Prove Clinical Value Lack of awareness Misleading data No incentives to change Disruption to status quo No stakeholders Knowledge Proved Clinical Value Minimal impact on status quo Believable data Gained stakeholders

  28. Slide 28: What is the future?

    What is the future? Antibiotic resistance Dwindling antibiotic pipeline Increasing demand for rational use of antibiotics Changes in re-imbursement structure

  29. Slide 29: Slide 29

  30. Slide 30: Emergence of CTX-M type ESBL in a Single Health Care System

    Emergence of CTX-M type ESBL in a Single Health Care System 88 proven ESBL isolates CTX-M = 59% SHV = 47% Most common sources: Urine (60%) Blood (21%) Respiratory (10%) JS Lewis II, and others. AAC. Nov 2007. 51(11):4015 (CHART)

  31. Slide 31: M. McKenna. Nature. Vol 499. July 2013

    M. McKenna. Nature. Vol 499. 25 July 2013

  32. Slide 32: Emergence of carbapenem resistant Enterobacteriaceae

    Emergence of carbapenem resistant Enterobacteriaceae M. McKenna. Nature. Vol 499. 25 July 2013

  33. Slide 33: Geographical Distribution of KPC Infections

    Geographical Distribution of Klebsiella pneumonia carbapenemase (KPC) Infections a

  34. Slide 34: Antibiotic development is dwindling

    1983-1987 1988-1992 1993-1997 1998-2002 ANTIBIOTIC DEVELOPMENT a IS DWINDLING 2008-2012

  35. Slide 35: Antibiotic Pipeline

    Antibiotic Pipeline HW Boucher. CID. 2013;56(12):1685-94 WT=wild type ESBL=Extended spectrum beta lactamase KPC=Klebsiella pneumoniae carbapenemase NDM-1=New Delhi metallo-^-lactamase ^-lactamase inhibitor Aminoglycoside Fluorocycline (targets ribosome) Peptide defense protein mimetic

  36. Slide 36: Calls for rational antibiotic use escalating

    Calls for rational antibiotic use escalating Obama budget boosts funds to fight 'nightmare bacteria' Liz Szabo, USA TODAY 2:32 p.m. EST March 4, 2014 Inappropriate use of antibiotics endangers patients' health.

  37. Slide 37: Four Core Actions to Prevent Antibiotic Resistance

    Four Core Actions to Prevent Antibiotic Resistance Preventing Infections, Preventing Spread of Resistance Tracking Improving Antibiotic Prescribing/Stewardship Developing New Drugs and Diagnostic Tests CDC. ANTIBIOTIC RESISTANCE THREATS in the United States, 2013

  38. Slide 38: Bundled Payments

    Bundled Payments MODEL 1: Retrospective Acute Care Hospital Stay Only MODEL 2: Retrospective Acute Care Hospital Stay plus Post-Acute Care MODEL 3: Retrospective Post-Acute Care Only MODEL 4: Acute Care Hospital Stay Only http://innovation.cms.gov/initiative/bundled-payments/#collapse-sepsisDetails

  39. Slide 39: Molecular Microbiology in 2014: Gastroenteritis Panels

    Molecular Microbiology in 2014: Gastroenteritis Panels Nathan A Ledeboer Associate Professor of Pathology Medical College of Wisconsin Medical Director, Microbiology and Molecular Pathology Dynacare Laboratories and Froedtert Hospital Medical Director, Laboratory Outreach and Reference Services Dyna

  40. Slide 40: Enteritis

    Enteritis Definition ^ 3 unformed stools in 24 hr period Scope of Problem Enteric illness affects millions yearly in US alone Mortality in infants and elderly Causes Foodborne Salmonella, Campylobacter, Y. enterocolitica, V. parahaemolyticus, ETEC, EPEC Environmental Cryptosporidium, Giardia, Isospo

  41. Slide 41: Enteritis characteristics and symptoms

    Characteristics/Symptoms Geography and travel history Season Age Duration of symptoms Watery? Bloody? Mucous? Current outbreaks/epidemics Enteritis Source: Centers for Disease Control Community or hospital/LTC Patient test (addition of C. difficile screen based on clinical presentation and exposure

  42. Slide 42: Laboratory Diagnoses - Culture

    Laboratory Diagnoses - Culture Screen (Non-specific)- Selective/differential culture BAP, MAC, XLD, HE, Campy, SMAC Plate ELISA/EIA Campylobacter Stx1/2 Can reduce TAT (direct testing), sensitivity +/-, add cost/labor Confirm Presumptive Positives- "Presumptive" colonies must be identified Many "Fal

  43. Slide 43: Unfunded Mandate

    Unfunded Mandate Benefit $$$ EHEC/STEC E. coli containing stx1 or stx2 Serotype o157 associated with stx2 carriage HUS in 2-10% of infected peoples CDC recommendation (2009) and Joint Commission updated standard (2013) to culture for O157 and use EIA/NAAT for stx1/2 Marcon, M.J., and Kiska, D.L.. JC

  44. Slide 44: Enteric Pathogen Panels

    Enteric Pathogen “Panels” > Potential Benefits Y Higher sensitivity for detection/identification of enteric pathogens Y More rapid TAT Y Potential Reduction in FTE dedicated to stool culture > Considerations Y Cost of molecular testing Y Technologist expertise * Test complexity ¥ Level of automation

  45. Slide 45: PCR vs Culture?

    Assay No. positive No. positive No. positive No. positive No. positive No. positive No. positive No. positive Assay Stx1 Stx1 Stx2 Stx2 Stx1 and Stx2 Stx1 and Stx2 Total Total Assay Specimens Patients Specimens Patients Specimens Patients Specimens Patients PCR 12 8 2 1 7 3 21 12 EIA Premier 3 2 0 0

  46. Slide 46: Is Culture the Gold Standard?

    Prospective study Preserved stools TP TN FP FN Total Sens Spec Campylobacter* 20 1113 0 6 1139 76.9% 100.0% Salmonella 20 1108 1 10 1139 66.7% 99.9% Shigella 15 1118 0 6 1139 71.4% 100.0% stx1/2 (EIA) 9 1121 0 9 1139 50.0% 100.0% Is Culture the "Gold Standard"? *C. coli or C. jejuni Culture sensitiv

  47. Slide 47: Enteric Pathogen Panels: Luminex xTAG GPP

    Enteric Pathogen "Panels" Luminex xTAG GPP FDA-cleared Targets Bacterial- Salmonella, Shigella, Campylobacter, E. coli 0157, ETEC (LS/ST), C. difficile* Viral - Norovirus (GI/II), Rotavirus A Parasites - Giardia, Cryptosporidium Comprehensive panel Requires nucleic acid extraction, PCR, hybridizatio

  48. Slide 48: Enteric Market Needs

    Enteric Market Needs Double-Digit-Plex Product WITH LIMITED HANDS-ON TIME Hospital's Traditional In-House Stool Culture Assay Double-Digit-Plex AND Sample- To-Result Product Pending FDA Clearance Up to 72 hours Multiple steps with tremendous amount of hands-on time Approved in 2013 Still significant

  49. Slide 49: Verigene Enteric Pathogens Panel (EP)

    Verigene Enteric Pathogens Panel (EP) Panel Targets Bacteria Viruses Toxins Campylobacter spp. Adenovirus stx1 Salmonella spp. Norovirus stx2 Shigella spp. Rotavirus Vibrio spp. Y. enterocolitica Comprehensive panel Sample-to-result Does not require separate extraction and amplification ~2.5 hour TA

  50. Slide 50: Enteric Pathogens Panel - Workflow

    Enteric Pathogens Panel - Workflow t=0 t=2h t=48h - 72 h Add sample to buffer EP Test Pathogen ID Transfer to EP Test Confirmatory ID/AST ID-YES! ID-No Finished 2 hrs t=5 min Stool sample collected in sterile container Traditional Stool Culture time to Identification

  51. Slide 51: Preliminary results for bacterial targets

    Preliminary results for bacterial targets -Verigene EP vs. Reference culture/Automated Phenotype Identification Stx 1 and Stx 2 EP Target Analyte Percent Agreement Percent Agreement EP Target Analyte Positive Negative Campylobacter 96.7% 99.1% Salmonella 96.6% 99.5% Shigella 98.1% 99.0% Vibrio 91.4%

  52. Slide 52: Molecular Enteric Pathogen Testing advantages

    Advantages Rapid rule out for common CA pathogens (high NPV/sens) Positive stools may not require further workup Work-up of negative stools can be more focused (O&P, allergic, toxin) Antibiotic stewardship Hold empiric therapy Salmonella, EHEC, noro ? may not require therapy; Campylobacter, Shigella

  53. Slide 53: Next Gen Development and Value

    Next Gen Development and Value Respiratory Flexible Reporting Clinician ordering patterns require two methods Allows for one platform conversion to molecular respiratory Will serve to accelerate market adoption from 500 labs today Sepsis Guidelines Require rapid understanding of 3 factors to direct

  54. Slide 54: Next generation Verigene

    Next generation verigene Customer-Directed Improvements Eliminate Reader step Consolidate consumables into one Room temperature stability Optimal footprint Deliver best-in-class interface in competitive timeline 54 Nanosphere investor day | next generation

  55. Slide 55: Financial considerations

    Financial considerations 55 Roger moody chief financial officer

  56. Slide 56: Financial leverage

    Financial leverage Top-line guidance does not require heroics-based on core business without improving trends Gross margin expansion projects necessary to achieve positive cash flow are underway and low risk Near-term menu provides SG&A leverage Positive cash flow can be achieved with near-term menu

  57. Slide 57: Top-Line Predictability

    Top-Line Predictability Top-line guidance based on core business 57 NANOSPHERE INVESTOR DAY | Financial considerations 57

  58. Slide 58: Low risk Margin Expansion

    Low risk Margin Expansion 58 NANOSPHERE INVESTOR DAY | Financial considerations

  59. Slide 59: Leverage Common Call Point

    Leverage Common Call Point Verigene Gram-Positive, Gram-Negative, Enteric and Respiratory Tests share common primary call point - Microbiology Lab Enteric is Less Complex Sale Economic value of reduced labor in the Microbiology Lab alone should justify adoption Model & Blueprint for Market Adoption

  60. Slide 60: Visibility and trend towards break-even

    Visibility and trend towards break-even 60 Annualized Revenue / ($ = thousands) Customer 2013 2014 Break-even US Microbiology Customers (YE) >200 >360 ~560 US Microbiology Customers Live (YE) >100 >200 ~460 US Microbiology Recurring Revenue Drivers: Respiratory 50 $ Blood Culture Gram-Positive 50 $

  61. Slide 61: Extending Cash runway

    Extending Cash runway Debt Restructure Recently revised terms of our debt agreement to extend $10 million second tranche availability to September 2014 Aspire Stock Purchase Commitment Put in place as an option to raise capital as needed to maintain acceptable liquidity Working Capital Evaluating sa

  62. Slide 62: Evidence of Our Belief

    Evidence of Our Belief Leverage in Customer Base Expanding Menu Best-in-Class Performance Differentiating Value in Protein De-Risked for Technology/Regulatory/Reimbursement Straightforward Cost Reduction Leverage Positive Cash Flow in Sight Focus on Execution and Delivering Results! 62 Nanosphere in

  63. Slide 63: Q&A

    Q&A 63

Nanosphere — Investor Day (March 2014) on 6ix